Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
The murine double minute 2 (MDM2)-p53 interaction inhibitor APG-115 demonstrates therapeutic potential in advanced malignancies. However, its molecular mechanism, especially for programmed death ligand 1 (PD-L1) immunotherapy modulation, remains poorly understood in thyroid cancer (TC). Herein, we conducted a series of in vitro and in vivo studies to investigate the therapeutic effect of APG-115 and the underlying molecular mechanisms in TC. We performed Cell Counting Kit (CCK-8) and cell scratch assay to assess the effect of APG-115 on the biological behavior of TC cells. Meanwhile, we performed animal experiments to investigate the therapeutic effect of APG-115 on TC in vivo. TC patient-derived organoids were further used to evaluate the potential value for clinical application of APG-115. Our results showed that APG-115 exhibited beneficial therapeutic effects in TC both in vitro and in vivo. Mechanistically, APG-115 restored the p53 antitumor effects by blocking MDM2-p53 binding and upregulating the PD-L1 expression. APG-115 downregulated Solute Carrier Family 7 Member 11 (SLC7A11) expression, contributing to lipid peroxidation and affecting PD-L1 expression in TC. Our study expands the clinical application value of APG-115 in cancer treatment, especially by further exploring the complex interplay between APG-115, PD-L1 immunotherapy, and ferroptosis.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12290942 | PMC |
| http://dx.doi.org/10.1021/acsomega.5c04710 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Deciphering pancreatobiliary intraductal oncocytic papillary neoplasms: integrative analysis of histomorphologic patterns, immunophenotypic markers, and emerging molecular biomarkers.
World J Surg Oncol
September 2025
Department of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, No.1 Shuaifuyuan Dongcheng District, Beijing, 100730, China.
Purpose: We reviewed recent advancements in the characterization of intraductal oncocytic papillary neoplasm (IOPN) of the pancreas, with a specific focus on developments in immunohistochemical markers, molecular pathology, and pathogenic mechanisms over the past ten years (2015-2024). Through comprehensive analysis of current literature, we aimed to elucidate the evolving understanding of IOPN's biological behavior and diagnostic features, while identifying potential areas for future research in this distinctive pancreatic neoplasm.
Methods: English-language articles on IOPN were searched from Pubmed from the first report of IOPN of the pancreas in 2015 to 2024.
Harnessing biomarkers to guide immunotherapy in esophageal cancer: toward precision oncology.
Clin Transl Oncol
September 2025
Department of Basic Science, College of Medicine, Princess Nourah bint Abdulrahman, University, P.O.Box 84428, 11671, Riyadh, Saudi Arabia.
Esophageal cancer (EC) is one of the most serious health issues around the world, ranking seventh among the most lethal types of cancer and eleventh among the most common types of cancer worldwide. Traditional therapies-such as surgery, chemotherapy, and radiation therapy-often yield limited success, especially in the advanced stages of EC, prompting the pursuit of novel and more effective treatment strategies. Immunotherapy has emerged as a promising option; nonetheless, its clinical success is hindered by variable patient responses.
View Article and Find Full Text PDFPD-L1 expression in locally advanced cervical cancer: A pilot cross clone comparison study.
Int J Radiat Oncol Biol Phys
September 2025
Department of Radiation Oncology, Advanced Centre for Treatment Research and Education in Cancer, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India. Electronic address:
Purpose: Recent immunotherapy trials in locally advanced cervical cancer report high PD-L1 positivity rates whereas academic multicentric initiatives report a lower PD-L1 positivity. These observations necessitate cross-clone comparison to understand the observed differences.
Methods: Two different clones used in previous multicentric international studies SP142 (BIOEMBRACE) and 22C3 (KEYNOTE-A18) were used to test PD-L1 positivity in a pilot cohort of FIGO 2018 stage III cervical cancer patients recruited in a phase III trial.
Dual-action nanotherapy: Temozolomide-loaded, anti-PD-L1 scFv-functionalized lipid nanocarriers for targeted glioblastoma therapy.
Eur J Pharm Sci
September 2025
Department of Neurology, Massachusetts General Hospital, Boston, MA, 02129, USA; Neuroscience Program, Harvard Medical School, Boston, MA, 02129, USA. Electronic address:
Glioblastoma (GBM) is a highly malignant brain tumor with limited treatment options and poor prognosis. GBM exhibits resistance to conventional therapies, including temozolomide (TMZ), radiotherapy, and immunotherapy, partly due to immunosuppressive mechanisms such as programmed death-ligand 1 (PD-L1) overexpression. To address these challenges, we developed TMZ-loaded nanostructured lipid carriers (NLCs) conjugated with anti-PD-L1 single-chain variable fragments (scFv) for dual chemo-immunotherapy.
View Article and Find Full Text PDFExploring Molecular Characteristics and Therapeutic Strategies for Primary Sinonasal Mucosal Melanoma with Distant Metastasis.
Lab Invest
September 2025
Department of Pathology and Laboratory Medicine, University of California, Irvine, CA, USA. Electronic address:
Sinonasal mucosal melanoma (SNMM) is a rare aggressive malignancy of the sinonasal tract. Due to its advanced clinical presentation and frequent late-stage diagnosis, the 5-year survival rate is less than 30%, with an even worse prognosis in patients with distant metastasis (SNMM-M). Therefore, characterizing the molecular landscape of SNMM may provide novel therapeutic targets for SNMM-M.
View Article and Find Full Text PDF